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Abstract
Background: The most common subtypes of Guillain-Barré syndrome (GBS) are acute
inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy
(AMAN). In the first days after the onset of weakness, standard nerve conduction studies
(NCS) may not distinguish GBS subtypes. Reduced nerve excitability may be an early
symptom of nerve dysfunction, which can be determined with the compound muscle
action potential (CMAP) scan. The aim of this study was to explore whether early
changes in motor nerve excitability in GBS patients are related to various subtypes.
Methods: Prospective case–control study in 19 GBS patients from The Netherlands
and 22 from Bangladesh. CMAP scans were performed within 2 days of hospital
admission and NCS 7–14 days after onset of weakness. CMAP scans were also per-
formed in age- and country-matched controls.
Results: CMAP scan patterns of patients who were classified as AMAN were distinctly
different compared to the CMAP scan patterns of the patients who were classified as
AIDP. Themost pronounced differenceswere found in the stimulus intensity parameters.
Conclusions: CMAP scans made at hospital admission demonstrate several character-
istics that can be used as an early indicator of GBS subtype.
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1 | INTRODUCTION
The Guillain-Barré syndrome (GBS) is a subacute disorder of the
motor and sensory nerves and nerve roots with a heterogeneous
pathophysiology and clinical course.1 GBS can be divided into distinct
subtypes depending on the extent of the peripheral nerve demyelin-
ation or axonal degeneration. In clinical practice, patients are classified
Abbreviations: AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute
motor axonal neuropathy; CMAP, compound muscle action potential; CTS, carpal tunnel
syndrome; DMCH, Dhaka Medical College and Hospital; GBS, Guillain-Barré syndrome; IQR,
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by standard nerve conduction studies (NCS) into acute inflammatory
demyelinating polyneuropathy (AIDP), and acute motor axonal neu-
ropathy (AMAN).2,3
NCS parameters have been related to the risk of developing
respiratory insufficiency and final outcome, which is highly variable in
GBS.4,5 Standard NCS provide information on nerve conduction
velocity and axonal loss. However, NCS abnormalities need to deviate
significantly from the normal range before the AIDP/AMAN distinc-
tion can be made.6 In the first week after symptom onset, NCS might
show only minor abnormalities.7 Furthermore, in this period, revers-
ible conduction failure can occur, mimicking signs of demyelination, in
patients who are later classified as AMAN.8 Reduced nerve excitability
may be the first electrophysiological manifestation of GBS9 and can
be assessed by the compound muscle action potential (CMAP) scan.10
This is a non-invasive, fast, and reproducible electrophysiological
method.11
In the current study, we investigated early changes in motor
nerve excitability by CMAP scan in GBS patients and studied if this
can be used as an early subtype discriminator.
2 | METHODS
2.1 | Patients and controls
A prospective case–control study was conducted in GBS patients and
age- and country-matched healthy subjects enrolled via Erasmus
Medical Center, Rotterdam, The Netherlands, and Dhaka Medical Col-
lege and Hospital (DMCH), Dhaka, Bangladesh. Inclusion criteria and
protocols for collection of clinical and electrophysiological data were
the same for both centers. All patients fulfilled the diagnostic criteria
for GBS, Miller Fisher syndrome,12 or other GBS variants and were
admitted to the hospital within 2 wk of onset of weakness. The
patients had no concomitant clinical conditions. Standardized clinical
scores including the GBS disability score,13 and Medical Research
Council (MRC) sum scores14 were determined for all patients at
admission. CMAP scans were performed within 2 days after hospital
admission by the same researcher. Standard NCS were performed
7–14 days after the onset of weakness.
A control was recruited for each patient. Controls were screened
to ensure that they had no neurological symptoms or diseases. In
Bangladesh, the controls were mainly derived from the same family as
the patient; for the Netherlands, the controls originated from an exis-
ting database that included healthy controls of various ages. Routine
NCS was performed in all control subjects to exclude median neurop-
athy at the wrist. CMAP scans were performed in the control group
using the same protocol as used in patients.
The study was approved by the local Medical Ethics Committee
of the Erasmus MC, The Netherlands, and by the Institutional
Review Board and the ethical committees at the International Cen-
tre for Diarrhoeal Disease Research, Dhaka, Bangladesh,
Bangladesh. All subjects and/or legal representatives gave informed
consent.
2.2 | Standard NCS
NCS and CMAP scans were performed on the non-dominant side.
Standardized motor NCS were performed of the ulnar, median, pero-
neal, and tibial nerves. Standardized sensory NCS were performed on
the ulnar, median, and sural nerves.15 If sensory potentials were pre-
sent, patients were tested for a carpal tunnel syndrome (CTS), by com-
paring the sensory conduction velocity of the median nerve across
the carpal tunnel to the sensory conduction velocity in the palm. For
motor nerves, the distal and proximal baseline-peak CMAP ampli-
tudes, distal motor latency, motor nerve conduction velocity, and F-
wave latencies were determined. For sensory nerves, the baseline-
peak sensory nerve action potential amplitude and sensory nerve con-
duction velocity were measured. Reference values were derived from
Buschbacher et al15 The NCS were classified according to the Hadden
electrophysiological criteria for GBS.2
All Dutch patients were warmed with hot water blankets.16 This
was not possible in Bangladesh, due to limited resources. However,
the temperature inside the hospital was as high as the outside
temperature.
2.3 | CMAP scans
CMAP scans were recorded using the CMAP scan application on a
Viking Select EMG system (CareFusion, San Diego, CA). The CMAPs
were obtained from the thenar muscles of the non-dominant hand
after stimulation of the median nerve at the wrist in all patients and
controls. All CMAP scans were performed by the same investigator
(J.D.).In CMAP scanning, the nerve is stimulated with gradually
increasing stimulus intensities (SIs), ranging from subthreshold to sup-
ramaximal values. With increasing SI the recorded CMAP will increase
until supramaximal values are reached. Plotting the CMAP amplitudes
against the corresponding SIs results in a dose–response curve which
defines the CMAP scan. It provides, through its dependence on SI,
information on nerve excitability.11 The presence of multiple large
steps points to underlying processes of axonal loss and rein-
nervation.17 We defined steps as clear gaps in the CMAP scan that
were bounded by plateaus at the upper and lower end of the gap,
each of which consisted of at least three consecutive responses of
about the same size (disregarding noise).11 The key parameters of the
CMAP scan are provided in Figure 1A. The entire procedure takes
approximately 5–10 min.
2.4 | Statistics
All data were tested for normality using Kolmogorov–Smirnov test.
Since the data were not normally distributed, non-parametric tests
were used for further analysis. Continuous variables were presented
as medians and interquartile ranges (IQRs) and were compared using
the Mann–Whitney-U test. Differences in proportions were deter-
mined using the Fishers exact test. All calculations were performed
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using SPSS 17.0 (SPSS Inc, Chicago, IL). Two-tailed tests were used
throughout, a P-value <.05 was considered to be statistically
significant.
Linear discriminant analysis was used to determine the indepen-
dent factors that were associated with the GBS-subtypes. Data from
controls were used to calculate the lower and upper limits of normal.
F IGURE 1 CMAP scans of control (A), AIDP patient (B), AMAN patient (C), and control, AIDP, and AMAN patient plotted in 1 panel (D). A,
Key variables of the CMAP scan that reflect excitability are: the SI activating the first motor unit (S0), the SI that elicits 50% of the maximum
CMAP (S50), the SI activating all motor units (S100), the SI-range (S100-S0), and the relative SI-range ((S100-S0)/ S0). Other key characteristics of
the CMAP scan are the maximum CMAP amplitude and the presence of steps, quantified as step percentage (step%).11 The presence of multiple
large steps points to underlying processes of axonal loss and reinnervation17
TABLE 1 Demography, neurological deficits, and CMAP scan of GBS patients
Parameter Dutch GBS patients (n = 19) Bangladeshi GBS patients (n = 22) P-value
Demography
Age (y) 50 (38–64) 25 (17–35) <.001
Sex (male/female) 17/2 15/7 .10
Neurological deficits
Cranial nerve involvement 11 (58%) 10 (45%) .55
Sensory deficits 17 (89%) 3 (14%) <.001
MRC sum score at entry 50 (47–60) 25 (18–43) <.001
GBS disability score at entry 3 (2–4) 4 (4–4) <.001
GBS subtypes <.001
Demyelinating 14 (74%) 1 (5%)
Axonal 0 (0%) 19 (86%)
Equivocal 5 (26%) 2 (9%)
Note: Data are presented as medians (IQR) or number (percentages).
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Values <2.5 percentile and > 97.5 percentile were considered
abnormal.
3 | RESULTS
Forty-one consecutive patients with GBS were included (32 males
[78%], median age 38 range 9–77 y). Nineteen patients originated
from The Netherlands and 22 patients from Bangladesh. Patients from
Bangladesh were significantly younger than patients from the Nether-
lands (P < .001).
The Dutch patients differed from the Bangladeshi patients with
respect to electrophysiological GBS-subtypes based on the results of
the standard NCS at 2 wk, according to the Hadden criteria2. GBS in
most of the Dutch patients was classified as demyelinating, whereas it
was classified as axonal in most patients from Bangladesh (Table 1).
3.1 | CMAP scan in controls
CMAP scanswere performed in all control subjects. TheCMAP scans from
controls from Bangladesh and The Netherlands were first analyzed sepa-
rately (Supporting Information Table SS1,which is available online). No dif-
ferences were found in CMAP scan characteristics between these two
groups. The data, therefore, were combined and used as a single control
group for the rest of the study. The upper and lower limits of normal for
the CMAP scan variables were calculated based on the 2.5 percentile and
97.5 percentile and presented Supporting Information Table SS1.
3.2 | CMAP scan in relation to GBS subtype
Based on the upper and lower limits of normal, 38 (93%) of the
41 patients showed abnormalities in the CMAP scan. Of these
41 patients, 15 (37%) were classified as AIDP, 19 (46%) as AMAN, and
TABLE 2 Baseline characteristics and CMAP scan characteristics of subgroups and age matched controls











Age (y) 50 (38–67) 25 (16–32) 36 (23–56) .001 .07 .02
Sex (males; n [%]) 13 (87%) 13 (68%) .21
Onset - CMAP scan
(days)
4 (3–9) 8 (5–10) .06
Onset – NCS (days) 13 (10–14) 13 (9–15) .70
CMAP scan
parameters
Max CMAP (mV) 3.6 (1.1–6.9) 2.3 (0.7–4.3) 10.4 (9.7–12.4) .26 <.001 <.001
S0 (mA) 10.0 (8.5–12.9) 7.1 (5.9–9.0) 7.4 (5.5–8.4) .006 <.001 .77
S50 (mA) 16.7 (16.0–26.1) 9.9 (8.2–10.8) 10.5 (7.9–11.4) <.001 <.001 .82
S100 (mA) 29.0 (26.0–48.9) 13.3 (11.8–16.4) 12.9 (10.8–14.2) <.001 <.001 .24
Absolute SI range
(mA)
20.5 (14.2–27.8) 6.0 (4.9–8.5) 5.4 (4.4–6.8) <.001 <.001 .11
Relative SI range 2.0 (1.2–2.4) 1.0 (0.6–1.2) 0.8 (0.6–1.0) .001 <.001 .16
Step % 8.1 (0.6–14.4) 6.5 (0.0–14.9) 1.7 (0.7–3.6) .63 .01 .03
Note: Data are presented as median (IQR) or as numbers (percentage).
Abbreviations: Absolute SI-range, S100-S0; Relative SI-range, (S100-S0)/S0; Step %, percentage of the CMAP scan that consists of steps.
F IGURE 2 Maximum CMAP amplitude versus SI range of
patients with NCS classified as demyelinating, axonal, and
equivocal, and of controls. Equivocal (stars) patients 1 and 2 are
Dutch patients with hyporeflexia and cranial nerve paresis. Patients
3 and 4, Dutch patients with classical Miller Fisher syndrome.
Patient 5, Dutch patient with ptosis, limb weakness, and areflexia.
Patient 6, patient from Bangladesh with severe limb weakness.
Patient 7, patient from Bangladesh with severe limb weakness and
cranial nerve paralysis
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7 (17%) as equivocal. The AMAN patients were significantly younger
than the AIDP patients (median 25 y and 50 y, respectively; P = .001).
CMAP scans performed at hospital admission showed a differ-
ence in SI variables between AIDP and AMAN patients. Typical exam-
ples of the CMAP scans of the patients with AIDP and AMAN are
provided in Figure 1B-D. The most pronounced differences were
found in the S50, S100, and absolute SI-range (Table 2).
Linear discriminant analysis identified the combination of maxi-
mum CMAP amplitude and absolute SI range as the parameters that
best separate the different subgroups. Plotting the maximum CMAP-
amplitude versus the absolute SI-range for the AIDP, AMAN, and con-
trols resulted in distinct patterns for the three groups (Figure 2).
3.3 | CMAP scans in equivocal patients
Seven patients were classified as equivocal based on NCS. Two showed
the “axonal pattern” (low amplitudes, normal SI ranges; patients 6 and
7 in Figure 2). These two patients came from Bangladesh and were clas-
sified as equivocal because they had conduction blocks in combination
with an otherwise axonal NCS. Two other equivocal patients had
CMAP scans that showed the “demyelinating pattern” (normal ampli-
tudes, high SI-ranges; patients 3 and 4). These were both Dutch
patients with a classical Miller Fisher syndrome (ophthalmoplegia,
ataxia, areflexia). In addition to absent H-reflexes, their standard NCS
were normal. The 3 remaining equivocal patients (patients 1,2 & 5) had
a “normal CMAP scan pattern”. Patient 1 and 2 were Dutch patients
with hyporeflexia and cranial nerve paresis. Patient 5 was a Dutch
patient with ptosis, mild limb weakness, and areflexia.
4 | DISCUSSION
In this study using the CMAP scan within the spectrum of patients
with GBS, we show that the majority of patients already have electro-
physiologically demonstrable nerve dysfunction at hospital admission.
In this very early stage of disease, 93% of the patients show various
types of abnormalities in the CMAP scan. In this stage of GBS, which
is important for early diagnosis, monitoring, and start of treatment,
abnormalities in nerve electrophysiology may support clinical decision
making. Furthermore, the results in the current study show that the
CMAP scan may also be used as a first and rapid screening technique,
that might aid early distinguishing between different subtypes of GBS.
4.1 | CMAP scan differences between AIDP
and AMAN
The CMAP scan patterns of patients who were classified as AMAN
were distinctly different compared to the CMAP scans patterns of the
patients who were classified as AIDP. The division into the “demyelin-
ating” and “axonal” subgroups was primarily based on differences in
SI variables. Probably, these differences in the excitability of
peripheral nerves reflect the variation in underlying pathophysiology
between these subtypes of GBS.
The mechanism of conduction failure and excitability changes in
AIDP is not well understood. One possible mechanism in the early
phase of demyelinating GBS might be related to the presence of
edema. Pathological studies found edema to be among the earliest
changes in peripheral nerves in GBS, followed by swelling and irregu-
larity of the myelin sheaths.18 This edema might result in a shunting
of the applied current away from the Ranvier nodes and, hence, result
in higher SIs needed to depolarize the axon.
If only a proportion of the axons are involved, this will lead to a
high S100 (the diseased axons are less excitable) in the CMAP scan,
with a normal S0 (determined by the healthy axons) and an increased
SI range (difference between SIs needed to activate the most healthy
axon [S0] and the least excitable axons [S100]). If all axons are
involved, this could result in an increase of all SI parameters. Further
experimental studies, preferably combined with pathology, are
required to elucidate these mechanisms.
For “axonal” GBS patients the presumed mode of action is medi-
ated by antibodies to various types of gangliosides or ganglioside
complexes,19 which leads to a complement-mediated disruption of
voltage-gated sodium (Nav) channel clusters at the Ranvier nodes.20
Dysfunction of the Nav-channels results in blockage of the action
potential independently of the applied current. Such an explanation is
consistent with both the reduced maximum CMAP amplitude and nor-
mal SIs in the CMAP scans of axonal patients.
The current classification of GBS patients as AMAN or AIDP is
based on findings in NCS. Multiple sets of electrophysiological criteria
have been developed to identify demyelination.2,3,7,21 Yet, no set is
generally accepted and the optimal time to perform NCS is still
debated. Furthermore, various studies have demonstrated the exis-
tence of reversible conduction failure and conduction blocks in pre-
sumably axonal patients, which makes the differentiation between
primary demyelinating GBS and primary axonal GBS even more diffi-
cult.2,3,22 Indeed, two of our patients from Bangladesh were classified
as equivocal because they had conduction blocks in combination with
otherwise axonal NCS. The CMAP scans of these two patients
showed the “axonal” pattern. The predominantly axonal NCS gives
reason to believe that, in these patients, the “axonal pattern” in the
CMAP scan truly results from an “axonal” GBS.
4.2 | Study limitations
For the discrimination between AMAN and AIDP, NCS data collected
and analyzed at 2 wk were used as a golden standard for subtyping.
However, we did not have an independent method, such as pathologi-
cal data, to confirm a definitive subtype diagnosis. Furthermore, since
we did not compare CMAP scans at admission with NCS at admission,
it is unknown if NCS performed at admission would also have been
able to discriminate between AMAN and AIDP at that time point.
For the purpose of the present study, we wished for patients with
AIDP and AMAN to be represented equally. Because of the
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geographical spread of these subtypes, we decided to include patients
from Bangladesh and The Netherlands.23 Bias might have been intro-
duced at this point. Most “axonal” patients originated from
Bangladesh, and most “demyelinating” patients came from The Neth-
erlands. Furthermore, the patients differed with regard to various
demographic characteristics including age. However, since we found
no differences between the CMAP scans of the younger Bangladeshi
controls and the older Dutch controls, we cautiously conclude that
the differences between our patients are not a result of just a geo-
graphical or age difference.
Due to infrastructural factors in Bangladesh, the time interval
between symptom onset and hospital admission in the AMAN
patients was longer than in the Dutch AIDP patients. Thus, the time
between symptom onset and first CMAP scan is longer for the AMAN
patients, although this difference was not statistically significant.
Future studies should preferentially include AMAN and AIDP patients
from the same country and also incorporate serial NCS performed at
the same time as the CMAP scan, and after at least 2 wk, since classi-
fication of the GBS subtype may change over time. This was not feasi-
ble in the current study. However, all of the AIDP patients had
sensory deficits, making it unlikely that they were erroneously classi-
fied as AMAN. It cannot be excluded that they might have been classi-
fied as an AMSAN in a later stage, however AMSAN is rare.
Although in healthy subjects the reproducibility of the CMAP
scan is good,11 this has not been tested in patients with GBS or other
neuropathies. Studies on the reproducibility of the CMAP scan in
patients with GBS and other neuropathies are needed. The CMAP
scan is performed only in the distal part of one nerve and in GBS the
pathological process is initially often segmental. Despite this limita-
tion, the CMAP scan is a promising, very easy, and quick method for
determining the GBS subtype, at least in a subset of patients.
ACKNOWLEDGMENTS
We thank J.J.de Rooi for his contribution to the statistical analysis.
We acknowledge the following donors, which provided support to the
icddr,b's activities: Government of the People's Republic of
Bangladesh, Global Affairs Canada (GAC), Swedish International
Development Cooperation Agency (Sida), and Department for Interna-
tional Development, UK (DFID).
CONFLICTS OF INTEREST
J.D., B.I., Q.M., E.M., G.V., J.B., H.E.: no conflict of interest.
Z.I. received funding from the Fogarty International Center, National
Institute of Neurological Disorders and Stroke of the National Insti-
tutes of Health, USA (under Award Number K43 TW011447) and
Annexon Biosciences (South San Francisco, CA 94080, USA). J.B.:
grant from Prinses Beatrix Spierfonds. B.J.: grants from Baxalta, grants
from CSL-Behring, grants from Grifols, grants from Prinses Beatrix
Spierfonds, grants from GBS-CIDP Foundation International, grants
from Annexon, grants from Hansa Biopharma, outside the submitted
work. Pv.D.: grants from Sanquin, Prinses Beatrix Spierfonds, Baxalta,
Grifols, other from Octapharma, outside the submitted work.
ETHICAL PUBLICATION STATEMENT
The authors confirm that we have read the Journal's position on
issues involved in ethical publication and affirm that this report is con-
sistent with those guidelines.
DATA AVAILABILITY STATEMENT
Data available on request from the authors.
REFERENCES
1. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lan-
cet. 2016;388(10045):717-727.
2. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological
classification of Guillain-Barre syndrome: clinical associations and out-
come. Plasma exchange/Sandoglobulin Guillain-Barre syndrome trial
group. Ann Neurol. 1998;44(5):780-788.
3. Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern
China. Relationship to campylobacter jejuni infection and anti-
glycolipid antibodies. Brain. 1995;118(Pt 3):597-605.
4. Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies
in Guillain-Barre syndrome: description and prognostic value. Ann
Neurol. 1988;23(4):354-359.
5. Durand MC, Porcher R, Orlikowski D, et al. Clinical and electro-
physiological predictors of respiratory failure in Guillain-Barre
syndrome: a prospective study. Lancet Neurol. 2006;5(12):1021-
1028.
6. Shahrizaila N, Goh KJ, Kokubun N, Abdullah S, Yuki N. Serial nerve
conduction studies provide insight into the pathophysiology of
Guillain-Barre and fisher syndromes. J Neurol Sci. 2011;309(1–2):
26-30.
7. Meulstee J, van der Meche FG. Electrodiagnostic criteria for poly-
neuropathy and demyelination: application in 135 patients with
Guillain-Barre syndrome. Dutch Guillain-Barre study group. J Neurol
Neurosurg Psychiatry. 1995;59(5):482-486.
8. Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and
controversies. Lancet Neurol. 2013;12(12):1180-1188.
9. Drenthen J, Maathuis EM, Visser GH, van Doorn PA, Blok JH,
Jacobs BC. Limb motor nerve dysfunction in Miller fisher syndrome.
J Peripher Nerv Syst. 2013;18(1):25-29.
10. Blok JH, Ruitenberg A, Maathuis EM, Visser GH. The electrophysio-
logical muscle scan. Muscle Nerve. 2007;36(4):436-446.
11. Maathuis EM, Drenthen J, Visser GH, Blok JH. Reproducibility of the
CMAP scan. J Electromyogr Kinesiol. 2011;21(3):433-437.
12. Sejvar JJ, Kohl KS, Gidudu J, et al. Brighton collaboration GBSWG.
Guillain-Barre syndrome and fisher syndrome: case definitions and
guidelines for collection, analysis, and presentation of immunization
safety data. Vaccine. 2011;29(3):599-612.
13. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled
trial prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):
750-753.
14. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agree-
ment in the assessment of muscle strength and functional abili-
ties in Guillain-Barre syndrome. Muscle Nerve. 1991;14(11):1103-
1109.
15. Buschbacher RM, Prahlow ND. Manual of Nerve Conduction Studies.
New York, NY: Demos Medical Publishing; 2006.
16. Drenthen J, Blok JH, van Heel EB, Visser GH. Limb temperature and
nerve conduction velocity during warming with hot water blankets.
J Clin Neurophysiol. 2008;25(2):104-110.
17. Sleutjes BT, Montfoort I, Maathuis EM, et al. CMAP scan discontinu-
ities: automated detection and relation to motor unit loss. Clin
Neurophysiol. 2014;125(2):388-395.
6 DRENTHEN ET AL.
18. Haymaker W, Kernohan JW. The Landry Guillain-Barre syndrome; a
clinicopathologic study of 50 fatal cases. Trans Am Neurol Assoc.
1948;73(73 Annual Meet):17-20.
19. Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies
in autoimmune neuropathies. Trends Immunol. 2013;34(9):
453-459.
20. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies
cause complement-mediated disruption of sodium channel clus-
ters in peripheral motor nerve fibers. J Neurosci. 2007;27(15):
3956-3967.
21. Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Elec-
trophysiological diagnosis of Guillain-Barre syndrome subtype: could
a single study suffice? J Neurol Neurosurg Psychiatry. 2015;86(1):
115-119.
22. Van den Bergh PYK, Pieret F, Woodard JL, et al. University of Louvain
GBSESG. Guillain-BarrE syndrome subtype diagnosis: a prospective
multicentric European study. Muscle Nerve. 2018;58:23–28.
23. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-
Barre syndrome associated with campylobacter infection in
Bangladesh. Neurology. 2010;74(7):581-587.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Drenthen J, Islam B, Islam Z, et al.
Changes in motor nerve excitability in acute phase Guillain-
Barré syndrome. Muscle & Nerve. 2021;1–7. https://doi.org/
10.1002/mus.27172
DRENTHEN ET AL. 7
